The company said the study showed that patients treated with ruxolitinib achieved clear to almost clear skin after eight weeks, with no new safety issues identified.
The study tested patients at least 12 years of age and suffering from eczema for two years or more.
Price: 79.95, Change: +0.65, Percent Change: +0.82
|Consensus Estimates for Industria de Diseno Textil's...|
|2020, 2021 Earnings Estimates for MarineMax Scaled Down|
|Hexagon AB's Consensus Projections for Q1, 2020, and...|
|2020, and 2021 Estimates for Humana Lowered but Q1 E...|
|Heidrick & Struggles' 2020 and 2021 Earnings Est...|